Poxel SA Sustainability Reports

Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious chronic diseases with metabolic pathophysiology. Its portfolio targets metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders.

Sector: Professional & technical services

Country: France

Exchange: Euronext Paris

LEI: 9695003OIX0T7NX72N26

FIGI: BBG001V0GP18

14 reports from 2015 to 2024

• Poxel SA 2024 Universal Registration Document
• Poxel SA 2023 Universal Registration Document
• Poxel SA 2022 Universal Registration Document
• Poxel SA 2022 Corporate Social Responsibility Report
• Poxel SA 2022 Corporate Social Responsibility Report